Expert Review of Pharmacoeconomics and Outcomes Research, 21, 1031-1042 Expert Review of Pharmacoeconomics and Outcomes Research, 21(5), 1031-1042. Expert Reviews Ltd. Expert Review of Pharmacoeconomics & Outcomes Research, 21(5), 1031-1042. Routledge/Taylor & Francis Group Expert review of pharmacoeconomics & outcomes research, 21(5), 1031-1042. Taylor & Francis Group Expert review of pharmacoeconomics & outcomes research, 21(5), 1031-1042. Taylor and Francis Ltd. Expert Review of Pharmacoeconomics and Outcomes Research, 21, 5, pp. 1031-1042 Lokkerbol, J, Wijnen, B, Ruhe, H G, Spijker, J, Morad, A, Schoevers, R, de Boer, M K, Cuijpers, P & Smit, F 2021, ' Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder ', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 21, no. 5, pp. 1031-1042 . https://doi.org/10.1080/14737167.2021.1844566 Expert Review of Pharmacoeconomics & Outcomes Research article-version (VoR) Version of Record Lokkerbol, J, Wijnen, B, Ruhe, H G, Spijker, J, Morad, A, Schoevers, R, de Boer, M K, Cuijpers, P & Smit, F 2021, ' Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder ', Expert review of pharmacoeconomics & outcomes research, vol. 21, no. 5, pp. 1031-1042 . https://doi.org/10.1080/14737167.2021.1844566